Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
Press Releases
Certara’s Synchrogenix Unit Provides Solution to Enable Pharma Compliance with EMA Policy 70
March 24, 2016
Newly-released guidance points to need for automated and scalable redaction technology
Certara Scientists to Participate in 12 Sessions at the ASCPT 2016 Annual Meeting
March 04, 2016
At ASCPT, Certara scientists will demonstrate how physiologically-based pharmacokinetic and pharmacodynamic modeling can help determine appropriate drug dosing in vulnerable populations and will also provide examples of using Model-Based Meta-Analysis to study the comparative effectiveness of different treatments
Certara Introduces Phoenix Technology Services to Optimize Pharma R&D Productivity
February 25, 2016
New Services Portfolio Supports Users of Certara’s Gold Standard Phoenix Software
Certara Expands Its Quantitative Systems Pharmacology Group; Appoints Professor Andrzej Kierzek
February 03, 2016
Certara established its market-leading position in QSP with the acquisition of XenologiQ, a UK-based QSP consultancy, in December 2015.
Japan Workshop August 2016
January 20, 2016
Drug development based on the information obtained from the central workshop physiological pharmacokinetic (PBPK ) Mode
Certara Launches a Strategic Drug Development Consulting Company in China
January 12, 2016
New company will use the full range of its modeling and simulation expertise to make the drug development process safer and more efficient
Certara Honored with 2015 R&D 100 Award for Its Muse Invent Software
December 14, 2015
Muse Invent enables biopharm researchers to design dream drug candidates, and then shows how to produce them in the lab
Certara Launches Version 15 of its Simcyp Population-based Simulator
December 08, 2015
Simcyp Simulator helps advance drug development and regulatory approval for the world’s top pharma companies
Certara Acquires Quantitative Systems Pharmacology Consultancy, XenologiQ
December 01, 2015
This transaction will strengthen Certara’s biosimulation capabilities, allowing it to link biological systems and disease processes
Certara Appoints Prof. Piet van der Graaf to Lead New Quantitative Systems Pharmacology Organization
December 01, 2015
Van der Graaf is professor of systems pharmacology, chair of pharmacology, and director of the Leiden Academic Centre for Drug Research at Leiden University in the Netherlands.
FDA Equips its Pharmacometrics Teams with Certara’s Phoenix Software
November 02, 2015
Partnership provides pharmacometric biosimulation solutions for multiple FDA centers
Certara Scientists to Give 22 Presentations at the AAPS Annual meeting
October 22, 2015
Their contributions include workshops, symposia, roundtables, posters, and a sunrise session
Japanese Medical Research and Development Agency Selects Phoenix WinNonlin Software
October 20, 2015
AMED was launched on April 1, 2015 and fulfills a similar role to the National Institutes of Health in the United States
Certara Scientists Participate in 9 Presentations at the North American ISSX Meeting
October 19, 2015
Diverse agenda underscores the widespread adoption of PBPK approaches throughout the drug development process
Certara Joins EU-ToxRisk – A Program Driving Mechanism-based Toxicity Testing and Risk Assessment
October 12, 2015
In a large (30 Million €) H2020-supported collaborative project, academia joins forces with small and medium-sized enterprises (SMEs), large industry, contract research organizations (CROs) and regulatory bodies to achieve a paradigm shift in toxicology towards a more efficient and animal-free chemical safety assessment.
Certara Scientists Participate in 14 Presentations at 6th American Conference on Pharmacometrics
October 02, 2015
Diverse agenda underscores the widespread adoption of pharmacometrics throughout the drug development process
Certara Presents Tuberculosis Biomarker Meta-Analysis and Pediatric Antibiotic Model at ASM
September 25, 2015
Certara presented two posters at the American Society for Microbiology’s (ASM’s) Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC).
Certara and Paidion Research Form Partnership Focused on Improving Pediatric Drug Development
September 10, 2015
The partnership harnesses Certara’s unmatched biosimulation (modeling and simulation) and regulatory writing capabilities, with Paidion’s regulatory strategy and pediatric clinical trial management expertise to address the critical challenges of bringing new therapies to children.
Certara Pharmacometrician Receives Faculty Appointment at University of Montreal
August 27, 2015
In this new role, Dr. Samer Mouksassi will teach clinicians and students how biosimulation can be used to improve drug development and enhance health outcomes.